Table 1.
Selected studies of adults with PMBCL treated in the rituximab era
| Reference | Study type | Treatment | Patients receiving RT, % | N | PFS, % |
|---|---|---|---|---|---|
| 19 | Retrospective | CHOP | Variable | 153 | 75 (5 y) |
| M/VACOP-B | |||||
| R-CHOP | |||||
| 22 | Retrospective | R-V/MACOP-B | 71 | 45 | 84 (5 y) |
| 20 | Prospective: subgroup analysis of MInT trial | R-CHOP-like (n=44) CHOP-like (n=43) |
70 | 87 | 78 (3-y EFS) 52 (3-y EFS) |
| 21 | Retrospective | R-CHOP CHOP |
76 | 76 48 | 81 (5 y) 47 (5 y) |
| 68 | Retrospective | R-CHOP | 77 | 63 | 68 (5 y) |
| 18 | Retrospective | R-VACOP-B (n = 30) R-CHOP (n = 13) VACAOP-B (n = 47) CHOP (n = 5) |
0 | 95 | 83 (5 y) 69 (5 y) 62 (5 y) 20 (5 y) |
| 42 | Retrospective | R-MACOP-B | 69 | 74 | 88 (10 y) |
| 69 | Prospective: subgroup analysis of UK NCRI RCHOP 14 vs 21 trial | R-CHOP 14 (n = 22) R-CHOP 21 (n = 28) |
58 | 50 | 84 (5 y) 80 (5 y) |
| 25, 26 | Prospective trial (n = 28) and subsequent patients treated according to the trial protocol (n = 26) | R-CHOP14-ICE | 0 | 54 | 78 (3 y) |
| 23 | Prospective | DA-EPOCH-R | 4 | 51 | 93 (3 y) |
| 29 | Retrospective | DA-EPOCH-R | 16 | 118 | 87 (3-y EFS) |
EFS, event-free survival; ICE, ifosfamide, carboplatin, etoposide; PFS, progression-free survival.